Listed by the USPTO as ESSEX, LAURA ANN
Tech Center 1600 • Art Units: 1624 1629 1645 1647 1649 1674 1675 1678 1699
This examiner grants 60% of resolved cases
ESSEX, LAURA ANN examines in tech center 1600 and art unit 1624. The profile includes 115 resolved cases and an allowance rate of 60.0%. The median time to allowance is 1311 days. The allowance rate is above half of the observed cases, while the median duration indicates that applicants should plan for an extended examination process.
The interview lift is 35.8%, showing a positive association with allowance outcomes. The Regents of the University of California, Biohaven Therapeutics Ltd., and Hoffmann-La Roche Inc. are the listed top companies. The top firms are BOZICEVIC, FIELD & FRANCIS LLP, Casimir Jones, S.C., and DANN, DORFMAN, HERRELL & SKILLMAN. Counsel may use interviews to clarify disputed technical positions and support a focused written record.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18339960 | METHODS FOR TREATING MULTIPLE SCLEROSIS WITH OCRELIZUMAB | Non-Final OA | Hoffmann-La Roche Inc. |
| 18045981 | Thermoresponsive or Shear-Thinning Injectable Gel Compositions for Treatment of Arthritis | Non-Final OA | GLOBUS MEDICAL, INC. |
| 18288679 | BIOREACTIVE PROTEINS CONTAINING UNNATURAL AMINO ACIDS | Non-Final OA | The Regents of the University of California |
| 18468633 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | Final Rejection | The Regents of the University of California |
| 18468639 | METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | Final Rejection | The Regents of the University of California |
| 17787152 | STABILIZATION OF MHC COMPLEXES | Final Rejection | The Regents of the University of California |
| 17047497 | METHODS AND COMPOSITIONS FOR TH9 CELL MEDIATED CANCER TREATMENT | Non-Final OA | The Cleveland Clinic Foundation |
| 18398367 | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF ALPHA | Non-Final OA | Sanofi |
| 17600957 | METHODS OF PREDICTING AND PREVENTING CANCER IN PATIENTS HAVING PREMALIGNANT LESIONS | Non-Final OA | Trustees of Boston University |
| 18354256 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | Non-Final OA | Ajinomoto Co., Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy60.0% of resolved applications examined by Laura Ann Essex were allowed (115 resolved cases), compared with 54.6% across Art Unit 1624 over the last five years.
This examiner's interview lift is +35.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Laura Ann Essex took 1,311 days on average from filing to allowance.
Laura Ann Essex examines applications in Art Unit 1624 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
